JPH0141132B2 - - Google Patents

Info

Publication number
JPH0141132B2
JPH0141132B2 JP57057178A JP5717882A JPH0141132B2 JP H0141132 B2 JPH0141132 B2 JP H0141132B2 JP 57057178 A JP57057178 A JP 57057178A JP 5717882 A JP5717882 A JP 5717882A JP H0141132 B2 JPH0141132 B2 JP H0141132B2
Authority
JP
Japan
Prior art keywords
carbon atoms
formula
group
cyclobutyl
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP57057178A
Other languages
English (en)
Japanese (ja)
Other versions
JPS57181043A (en
Inventor
Edowaado Jefurei Jeemusu
Kozuritsuku Antonin
Chaaruzu Uirumusuhaasuto Eritsuku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of JPS57181043A publication Critical patent/JPS57181043A/ja
Publication of JPH0141132B2 publication Critical patent/JPH0141132B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/50—Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/42—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrolysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • C07C49/237—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/567—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/40—Unsaturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP57057178A 1981-04-06 1982-04-06 Arylcyclobutylamine derivative as medicine and manufacture Granted JPS57181043A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8110709 1981-04-06

Publications (2)

Publication Number Publication Date
JPS57181043A JPS57181043A (en) 1982-11-08
JPH0141132B2 true JPH0141132B2 (show.php) 1989-09-04

Family

ID=10520962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57057178A Granted JPS57181043A (en) 1981-04-06 1982-04-06 Arylcyclobutylamine derivative as medicine and manufacture

Country Status (6)

Country Link
US (5) US4522828A (show.php)
JP (1) JPS57181043A (show.php)
BE (1) BE892758A (show.php)
BR (1) BR1100070A (show.php)
ZA (1) ZA821577B (show.php)
ZM (1) ZM2482A1 (show.php)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU3366389A (en) * 1988-03-25 1989-10-16 Marion Laboratories, Inc. Piperidine ring modified phencyclidine analogs as anticonvulsants
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
AU4542993A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
GB9524681D0 (en) * 1995-12-02 1996-01-31 Knoll Ag Chemical process
EP0780127A1 (en) 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
WO2000056150A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of premenstrual syndrome
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056149A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating anxiety disorders
TR200102699T2 (tr) * 1999-03-19 2002-03-21 Knoll Gmbh Kronik mafsal bozukluĞunun (osteoarthritis) tedavisi
WO2000056311A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Control of metabolism
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
AU3894300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pharmacology of drug misuse and other addictive disorders
US6552087B1 (en) * 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
MXPA01009468A (es) 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de hipertension pulmonar.
WO2000056151A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating obsessive-compulsive disorder
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US7129378B2 (en) * 2002-04-10 2006-10-31 Apsinterm, Llc Method of preparing amine stereoisomers
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
EP1545484A4 (en) * 2002-10-05 2010-01-13 Hanmi Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITION WITH CRYSTALLINE SIBUTRAMINE METHANSULFONATE HEMIHYDRATE
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0230134D0 (en) * 2002-12-24 2003-01-29 Amedis Pharm Ltd Compounds and their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
NZ577031A (en) * 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR101397913B1 (ko) 2005-05-30 2014-05-26 엠에스디 가부시키가이샤 신규 피페리딘 유도체
WO2007005940A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
CL2007002044A1 (es) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd Polimorfo cristalino de la sal hemicalcica del acido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxiheptanoico; composicion farmaceutica; y uso para el tratamiento de la diabetes, enf
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
CN102164488B (zh) * 2008-03-19 2015-02-25 奥里梅德制药公司 有益于治疗中枢神经系统疾病和病症的新化合物
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
RU2015137145A (ru) 2013-02-28 2017-04-03 Пфайзер Инк. Новые жидкие композиции с повышенной стабильностью
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IL283182B2 (en) 2018-11-20 2025-10-01 Tes Pharma S R L Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
TWI850346B (zh) * 2019-03-11 2024-08-01 美商Ｒ Ｐ 先靈爾科技公司 於軟凝膠中改善api穩定性

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
FR2260336A2 (show.php) * 1974-02-13 1975-09-05 Sandoz Sa
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
US4100299A (en) * 1976-01-05 1978-07-11 Mitsubishi Chemical Industries Limited Pharmaceutically active 2-omega-aminoalkoxydiphenylmethylmethanes
US4071552A (en) * 1976-05-19 1978-01-31 Ayerst Mckenna And Harrison Ltd. Aryloxy aminobutanols, their preparation and use thereof
SE414305B (sv) * 1976-08-25 1980-07-21 Astra Laekemedel Ab Analogiforfarande for framstellning av eventuellt substituerade 2-amino-6-fenyl-5,5dimetyl 3-hexanon med antidepressiv aktivitet
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same

Also Published As

Publication number Publication date
US4746680A (en) 1988-05-24
ZA821577B (en) 1983-03-30
JPS57181043A (en) 1982-11-08
BR1100070A (pt) 1999-10-05
US4522828B1 (show.php) 1993-05-11
US4522828A (en) 1985-06-11
BE892758A (fr) 1982-10-05
US4814352A (en) 1989-03-21
ZM2482A1 (en) 1983-07-21
US4767790A (en) 1988-08-30
US4806570A (en) 1989-02-21

Similar Documents

Publication Publication Date Title
JPH0141132B2 (show.php)
KR900000274B1 (ko) 1-(1-아릴사이클로부틸)알킬아민 유도체의 제조방법
AU2007205114B2 (en) Cycloalkylamines as monoamine reuptake inhibitors
US3532749A (en) N'-propargyl-n**2-cyclopropyl-ethylenediamines and the salts thereof
NZ527012A (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD
DE19518988A1 (de) Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
US4443449A (en) Arylcyclobutylalkylamines and anti-depression composition and methods using same
KR900005256B1 (ko) 페닐사이클로부틸메틸아민 유도체의 제조방법
CA2028893C (en) Morpholinols, their prepation and use
DK170040B1 (da) Phenoxyethylaminderivater og farmaceutisk acceptable salte deraf, disse forbindelsers fremstilling samt farmaceutisk præparat indeholdende forbindelserne
JPS62120349A (ja) α−（アミノアルキル）アリ−ル酢酸誘導体
MX2008008807A (en) Cycloalkylamines as monoamine reuptake inhibitors
CH435286A (fr) Procédé de préparation de dérivés de la pyrrolidine